Hangeshashinto improves the completion rate of chemoradiotherapy and the nutritional status in patients with head and neck cancer.

@article{Hatakeyama2015HangeshashintoIT,
  title={Hangeshashinto improves the completion rate of chemoradiotherapy and the nutritional status in patients with head and neck cancer.},
  author={Hiromitsu Hatakeyama and Hiroki Takahashi and Nobuhiko Oridate and Rinnosuke Kuramoto and Keishi Fujiwara and Akihiro Homma and Hiroshi Takeda and Satoshi Fukuda},
  journal={ORL; journal for oto-rhino-laryngology and its related specialties},
  year={2015},
  volume={77 2},
  pages={100-8}
}
PURPOSE Severe oral and pharyngeal mucositis is one of the most critical toxicities known to lead to the discontinuation of chemoradiotherapy (CRT) for head and neck cancer (HNC). Hangeshashinto (TJ-14) is a Kampo medicine that relieves chemotherapy-induced oral mucositis. We investigated the effect of TJ-14 on mucositis, nutritional status, and the… CONTINUE READING